Gapping up
In reaction to strong earnings/guidance: CLIR +10.5%, PAY +9.3%, PRMW +8.3%, (light volume), DMND +5.8%, AXAS +4.8%, CYTX +4.2%, SAFT +3%, PUK +2.9%, QIWI +2.6%, NCS +2.5%, NJR +1.7%, EVOL +1.5%.
M&A news: EPL +29.2% (to be acquired by Energy XXI (EXXI) for total consideration of $2.3 bln; consideration to be received by EPL stockholders is valued at $39.00 per EPL share).
Select metals/mining stocks trading higher: IAG +2.4%, HL +2.1%, PAAS +1.8%, SVM +1.8%, GFI +1.8%, AU +1.7%, AUY +1.7%, NEM +1.5%, HMY +1.5%, SLW +1.4%, AG +1.4%, GDX +1.3%.
Other news: OXGN +134.3% (announces positive topline results from randomized phase 2 study GOG186I of ZYBRESTAT in combination with Avastin for recurrent ovarian cancer), RTIX +19.5% (co received CE Mark approval for Fortiva Porcine Dermis), CMRX +11.5% (reaches agreement with the FDA for the immediate initiation of a pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients), CLTX +6.6% (Provides Update on MRX-6 From FDA Pre-IND Meeting; MRX-6 to advance into Phase II trials in US upon filing of IND expected in 4Q14), TGTX +4.5% (announced $18.1 mln underwritten sale of common stock to a single institutional investor), TASR +1.8% (announces multiple orders of its TASER brand conducted electrical weapons and its next generation Smart Weapons), PSTI +1.3% (presents preclinical results for Pluristem's PLX-PAD Cells in tendon injury), SMLP +0.9% (prices upsized public offering of common units, also upgraded to Outperform from Neutral at Robert W. Baird).
Analyst comments: RAD +3.3% (upgraded to Buy from Neutral at Goldman), MCK +0.9% (added to Conviction Buy list at Goldman), ANGO +0.9% (upgraded to Outperform from Mkt Perform at Raymond James), WAG +0.9% (tgt raised to $90 from $67 at UBS), MLNX +0.7% (initiated with a Buy at Nomura)
M&A news: EPL +29.2% (to be acquired by Energy XXI (EXXI) for total consideration of $2.3 bln; consideration to be received by EPL stockholders is valued at $39.00 per EPL share).
Select metals/mining stocks trading higher: IAG +2.4%, HL +2.1%, PAAS +1.8%, SVM +1.8%, GFI +1.8%, AU +1.7%, AUY +1.7%, NEM +1.5%, HMY +1.5%, SLW +1.4%, AG +1.4%, GDX +1.3%.
Other news: OXGN +134.3% (announces positive topline results from randomized phase 2 study GOG186I of ZYBRESTAT in combination with Avastin for recurrent ovarian cancer), RTIX +19.5% (co received CE Mark approval for Fortiva Porcine Dermis), CMRX +11.5% (reaches agreement with the FDA for the immediate initiation of a pilot trial of open-label brincidofovir for the treatment of adenovirus infections in immunocompromised patients), CLTX +6.6% (Provides Update on MRX-6 From FDA Pre-IND Meeting; MRX-6 to advance into Phase II trials in US upon filing of IND expected in 4Q14), TGTX +4.5% (announced $18.1 mln underwritten sale of common stock to a single institutional investor), TASR +1.8% (announces multiple orders of its TASER brand conducted electrical weapons and its next generation Smart Weapons), PSTI +1.3% (presents preclinical results for Pluristem's PLX-PAD Cells in tendon injury), SMLP +0.9% (prices upsized public offering of common units, also upgraded to Outperform from Neutral at Robert W. Baird).
Analyst comments: RAD +3.3% (upgraded to Buy from Neutral at Goldman), MCK +0.9% (added to Conviction Buy list at Goldman), ANGO +0.9% (upgraded to Outperform from Mkt Perform at Raymond James), WAG +0.9% (tgt raised to $90 from $67 at UBS), MLNX +0.7% (initiated with a Buy at Nomura)